Advertisement
Journal of Clinical Oncology  
Search for:
Limit by:
  Browse by Subject or Issue
Home Search or Browse JCO My JCO Subscriptions Customer Service Site Map

Journal of Clinical Oncology, Vol 23, No 24 (August 20), 2005: pp. 5795-5804
© 2005 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2005.11.601

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a colleague
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Save to my personal folders
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Van Glabbeke, M.
Right arrow Articles by Judson, I. R.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Van Glabbeke, M.
Right arrow Articles by Judson, I. R.

Initial and Late Resistance to Imatinib in Advanced Gastrointestinal Stromal Tumors Are Predicted by Different Prognostic Factors: A European Organisation for Research and Treatment of Cancer–Italian Sarcoma Group–Australasian Gastrointestinal Trials Group Study

Martine Van Glabbeke, Jaap Verweij, Paolo G. Casali, Axel Le Cesne, Peter Hohenberger, Isabelle Ray-Coquard, Marcus Schlemmer, Allan T. van Oosterom, David Goldstein, Raf Sciot, Pancras C.W. Hogendoorn, Michelle Brown, Rossella Bertulli, Ian R. Judson

From the European Organisation for Research and Treatment of Cancer Data Center, Brussels; University Hospital Gasthuisberg, Leuven, Belgium; Erasmus University Medical Center, Rotterdam; Leiden University Medical Center, Leiden, the Netherlands; Istituto Tumori, Milano, Italy; Institut Gustave Roussy, Villejuif; Centre Leon Berard, Lyon, France; Charite Campus Buch, Robert Roessle Hospital, Berlin; Klinikum Grosshadern; Gesellschaft für Strahlenforschung–National Research Center for Environmental and Health, Munich, Germany; Prince of Wales Hospital, Randwick, Australia; and Royal Marsden Hospital, London, United Kingdom

Address reprint requests to Martine Van Glabbeke, MD, European Organisation for Research and Treatment of Cancer Data Center, Av. E. Mounier, 83, bte 8, B1200 Brussels, Belgium; e-mail: mvg{at}eortc.be

PURPOSE: The aim of this study was to identify factors predicting initial and late resistance of GI stromal tumor (GIST) patients to imatinib and to document the dose-response relationship in the prognostic subgroups. This study is based on the European Organisation for Research and Treatment of Cancer–Italian Sarcoma Group–Australasian Gastrointestinal Trials Group randomized trial comparing two doses of imatinib in advanced disease.

PATIENTS AND METHODS: Initial resistance was defined as progression within 3 months of randomization, and late resistance was defined as progression beyond 3 months. Investigated cofactors include imatinib dose, age, sex, performance status, original disease site, site and size of lesions at trial entry, and baseline hematologic and biologic parameters.

RESULTS: Initial resistance was recorded for 116 (12%) of 934 assessable patients and was independently predicted by the presence of lung and absence of liver metastases, low hemoglobin level, and high granulocyte count. Among 818 patients who were alive and progression free at 3 months, 347 subsequent progressions were recorded, and late resistance was independently predicted by high baseline granulocyte count, primary tumor outside of the stomach, large tumor size, and low initial imatinib dose. The impact of initial dose on late resistance was mainly significant in patients with a high baseline granulocyte count (> 5.109/L) and in patients with tumors of GI origin outside of the stomach and small intestine.

CONCLUSION: Our study identifies patients for whom initial and/or long-term treatment needs to be improved and patients who require a high initial dose. Correlation of these results with immunohistochemistry and molecular parameters may further help to understand the biologic mechanisms of resistance.

Supported by an unrestricted grant from Novartis Oncology and by grant Nos. 2U10 CA11488-29 through 5U10 CA11488-34 from the National Cancer Institute (Bethesda, MD).

Presented in part at the 10th Annual Meeting of the Connective Tissue Oncology Society, Montreal, Quebec, Canada, November 11-13, 2004.

The contents of this article are solely the responsibility of the authors and do not necessarily represent the official views of the National Cancer Institute.

Authors' disclosures of potential conflicts of interest are found at the end of this article.




This article has been cited by other articles:


Home page
Clin. Cancer Res.Home page
C. Mussi, H.-U. Schildhaus, A. Gronchi, E. Wardelmann, and P. Hohenberger
Therapeutic Consequences from Molecular Biology for Gastrointestinal Stromal Tumor Patients Affected by Neurofibromatosis Type 1
Clin. Cancer Res., July 15, 2008; 14(14): 4550 - 4555.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
C. D. Blanke, G. D. Demetri, M. von Mehren, M. C. Heinrich, B. Eisenberg, J. A. Fletcher, C. L. Corless, C. D.M. Fletcher, P. J. Roberts, D. Heinz, et al.
Long-Term Results From a Randomized Phase II Trial of Standard- Versus Higher-Dose Imatinib Mesylate for Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing KIT
J. Clin. Oncol., February 1, 2008; 26(4): 620 - 625.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
C. D. Blanke, C. Rankin, G. D. Demetri, C. W. Ryan, M. von Mehren, R. S. Benjamin, A. K. Raymond, V. H.C. Bramwell, L. H. Baker, R. G. Maki, et al.
Phase III Randomized, Intergroup Trial Assessing Imatinib Mesylate At Two Dose Levels in Patients With Unresectable or Metastatic Gastrointestinal Stromal Tumors Expressing the Kit Receptor Tyrosine Kinase: S0033
J. Clin. Oncol., February 1, 2008; 26(4): 626 - 632.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
S. Sleijfer, E. Wiemer, C. Seynaeve, and J. Verweij
Improved Insight into Resistance Mechanisms to Imatinib in Gastrointestinal Stromal Tumors: A Basis for Novel Approaches and Individualization of Treatment
Oncologist, June 1, 2007; 12(6): 719 - 726.
[Abstract] [Full Text] [PDF]


Home page
JCOHome page
L. Q.M. Chow and S. G. Eckhardt
Sunitinib: From Rational Design to Clinical Efficacy
J. Clin. Oncol., March 1, 2007; 25(7): 884 - 896.
[Abstract] [Full Text] [PDF]


Home page
J. Mol. Diagn.Home page
J. Lasota, B. Wasag, S. E. Steigen, J. Limon, and M. Miettinen
Improved Detection of KIT Exon 11 Duplications in Formalin-Fixed, Paraffin-Embedded Gastrointestinal Stromal Tumors
J. Mol. Diagn., February 1, 2007; 9(1): 89 - 94.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
N. P. Agaram, P. Besmer, G. C. Wong, T. Guo, N. D. Socci, R. G. Maki, D. DeSantis, M. F. Brennan, S. Singer, R. P. DeMatteo, et al.
Pathologic and Molecular Heterogeneity in Imatinib-Stable or Imatinib-Responsive Gastrointestinal Stromal Tumors
Clin. Cancer Res., January 1, 2007; 13(1): 170 - 181.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
C. Delbaldo, E. Chatelut, M. Re, A. Deroussent, S. Seronie-Vivien, A. Jambu, P. Berthaud, A. Le Cesne, J.-Y. Blay, and G. Vassal
Pharmacokinetic-Pharmacodynamic Relationships of Imatinib and Its Main Metabolite in Patients with Advanced Gastrointestinal Stromal Tumors.
Clin. Cancer Res., October 15, 2006; 12(20): 6073 - 6078.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
E. Wardelmann, K. Biermann, S. Merkelbach-Bruse, H.-U. Schildhaus, N. Thomas, R. Buttner, T. Pietsch, T. Heinicke, N. Speidel, D. Pink, et al.
Polyclonal resistance in gastrointestinal stromal tumor treated with sequential kinase inhibitors.
Clin. Cancer Res., October 15, 2006; 12(20): 6206 - 6206.
[Full Text] [PDF]



About
JCO
 Editorial
Roster
 Advertising
Information
 Librarians &
Institutions
 Rights &
Permissions
 PDA Services

Copyright © 2005 by the American Society of Clinical Oncology, Online ISSN: 1527-7755. Print ISSN: 0732-183X
Terms and Conditions of Use
  HighWire Press HighWire Press™ assists in the publication of JCO Online